PRRT2 and cancer: It should however be noted that Y‐27632, the ROCK inhibitor that was used in this study, exhibits off‐target effects, targeting protein kinases like PKA,[46, 47, 48] PKC,[47] as well as PRK‐2.[49] As such, the actual involvement of Rho/ROCK signaling in THBS2‐mediated cancer and stemness phenotype will need to be further supported by additional specific Rho/ROCK assays in the future.